Investment Rating - The investment rating for Salesforce (CRM) is "Buy" (maintained) [1] Core Insights - In FY25Q4, Salesforce reported a revenue of $9.99 billion, a year-over-year increase of 7.6%, exceeding consensus expectations by 0.3%. Subscription revenue reached $9.45 billion, growing 8.0% year-over-year, but fell short of expectations by 0.7%. Net profit for the quarter was $1.71 billion, up 18.1% year-over-year, surpassing expectations by 8.2%. The non-GAAP operating margin was 33.1%, an increase of 1.7 percentage points year-over-year [3][4] - The company's Remaining Performance Obligations (RPO) reached a record high of $63.4 billion, growing 11.4% year-over-year, exceeding expectations by 2.3%. The current RPO (cRPO) segment was $3.2 billion, up 6.4% year-over-year, also surpassing expectations by 1.4% [5] - Salesforce continues to strengthen its AI capabilities, with over 3,000 paid customers for AgentForce and more than 400 orders exceeding $1 million. The company signed a cloud computing partnership with Alphabet, allowing its customers to run CRM software on Google Cloud, marking a shift from reliance on Amazon's cloud services [4][6] Financial Performance Summary - For FY2025, Salesforce's revenue is projected at $37.895 billion, with a year-over-year growth of 8.7%. The non-GAAP net profit is expected to be $9.93 billion, reflecting a 22.8% increase year-over-year. The gross margin is forecasted at 77.2% [10][12] - The company has revised its guidance for Q1 and the full year of FY26, expecting Q1 revenue between $9.71 billion and $9.76 billion, a year-over-year growth of 6%-7%, below market expectations of $9.91 billion. The full-year revenue forecast is $40.5 billion to $40.9 billion, a growth of 7%-8%, also below market expectations of $41.5 billion [6][7] Investment Recommendations - The report anticipates non-GAAP net profits for FY26, FY27, and FY28 to be $10.68 billion, $11.90 billion, and $12.81 billion, respectively, with year-over-year growth rates of 7.5%, 11.5%, and 7.6%. The corresponding price-to-earnings (P/E) ratios are projected to be 27.5, 24.7, and 23.0 [7][10]

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The report highlights the ongoing active research in life sciences and the global wave of biotechnology revolution, which is accelerating integration into economic and social development, providing new solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [3][4]. Summary by Sections 1.1 Secondary Market Performance - The synthetic biology sector saw an overall increase of 6.17% in stock performance during the week of February 24 to February 28, 2025, ranking first among sectors [14]. 1.2 Company Business Progress - Domestic companies are making significant advancements, such as: - Zhongyuan Biological's 350,000 tons/year green methanol project is progressing with the first phase expected to be completed in 24 months [22]. - Longi Green Energy and China Energy Construction Group signed a project for 300,000 tons/year green methanol, with a total investment of 6 billion yuan [22]. - Henghui Security's biodegradable polyester rubber project is on track to start production in Q4 2025 [23]. 1.3 Industry Financing Tracking - Financing activities in the synthetic biology sector are accelerating, with nearly a hundred companies completing new rounds of financing at the beginning of 2025. Notable examples include: - Nanjing Senqi New Materials Technology completed a multi-million yuan financing round, focusing on bio-based nanocellulose [28]. - Vivici, a precision fermentation dairy product company, raised €32.5 million in Series A funding to launch a new product [28]. 1.4 Company R&D Directions - Domestic research institutions are achieving breakthroughs in bio-based materials, such as: - The Ningbo Institute of Materials Technology and Engineering has made progress in synthesizing bio-based long-chain polyols [31]. - Wanhua Chemical launched a bio-based 1,3-butanediol product aimed at the cosmetics industry, emphasizing sustainability and low carbon emissions [31].

[Table_IndNameRptType] 基础化工 行业周报 卫星化学业绩预告同比大幅增长，硫磺、钾肥等价格上涨 [Table_IndRank] 行业评级：增持 报告日期： 2025-03-04 [Table_Chart] 行业指数与沪深 300 走势比较 -25% -14% -3% 8% 19% 30% 3/24 6/24 9/24 12/24 3/25 基础化工 沪深300 [Table_Author] 分析师：王强峰 执业证书号：S0010522110002 电话：13621792701 邮箱：wangqf@hazq.com 分析师：刘天其 执业证书号：S0010524080003 电话：17321190296 邮箱：liutq@hazq.com 主要观点： ⚫[Table_Summary] 行业周观点 本周（2025/2/22-2025/2/28）化工板块整体涨跌幅表现排名第 18 位，涨跌幅为-0.94% ，走势处于市场整体走势中下游。上证综指涨跌 幅为-1.72%，创业板指涨跌幅为-4.87%，申万化工板块跑赢上证综指 0.78 个百分点，跑赢创业板指 3.93 个百分点。 ⚫ 2025 年化 ...

证券研究报告 华安研究• 拓展投资价值 核心观点： 证券研究报告 医疗器械专题之脑机接口 ——中国脑机接口行业现状与展望 分析师：谭国超（S0010521120002）邮箱: tangc@hazq.com 分析师：钱琨（S0010524110002）邮箱：qiankun@hazq.com 2025年3月3日 华安证券研究所 华安证券研究所 敬请参阅末页重要声明及评级说明 2 n 政策引导+技术突破，全球脑机接口产业进入高速发展阶段，中国非侵入式脑机接口技术全球领先。脑机接口正进入爆发式增长 阶段，根据前瞻产业研究院预测，2023年全球市场规模达19.8亿美元，预计2028年将突破60亿美元，五年复合年增长率25.22%。中 国起步较晚，但政策支持力度显著：2024年工信部将其列为"十大标志性未来产业"，北京、上海等地提出2030年实现核心技术自 主可控及临床应用目标。中国围绕非侵入式脑机接口方向，实现弯道超车，首创实现"双环路"脑机交互系统，打破了传统脑机 接口的信息交互，并极大突破了操控时间的限制，该技术突破使得中国在非侵入式脑机接口领域处于全球领先地位。 n 医疗健康领域商业化进程领先，多场景应用潜力逐步 ...

安科生物（ [Table_StockNameRptType] 300009） 公司覆盖 | 投资评级：买入 [Table_Rank] | | | --- | --- | | 首次覆盖 | | | 报告日期： 2025-02-27 | | | [Table_BaseData] 收盘价（元） | 8.80 | | 近 12 个月最高/最低（元） | 11.77/7.41 | | 总股本（百万股） | 1,673 | | 流通股本（百万股） | 1,222 | | 流通股比例（%） | 73.04 | | 总市值（亿元） | 147 | | 流通市值（亿元） | 108 | [公司价格与沪深 Table_Chart] 300 走势比较 -31% -15% 1% 16% 32% 2/24 5/24 8/24 11/24 2/25 安科生物 沪深300 [Table_Author] 分析师：谭国超 执业证书号：S0010521120002 邮箱：tangc@hazq.com 分析师：陈珈蔚 执业证书号：S0010524030001 邮箱：chenjw@hazq.com 联系人：李雨涵 执业证书号：S0010123070 ...

Investment Rating - Industry Investment Rating: Overweight [1] Core Insights - The photovoltaic sector is experiencing a slight price increase in N-type modules due to a surge in demand driven by new policy implementations, indicating a potential recovery in Q2 2025 [3][11] - The wind power sector is witnessing a positive sentiment with the commencement of offshore wind projects, suggesting an upward trend in the market [4][25] - The energy storage segment is expected to see valuation recovery due to rising prices in South Africa and increased demand in Australia [8][32] - The hydrogen energy sector is gaining attention with the IPO of a national hydrogen technology company, indicating a potential investment window [8][38] - The electric grid equipment sector anticipates over 800 billion yuan in investments this year, driven by the initiation of several ultra-high voltage projects [8][41] - The electric vehicle market is focusing on solid-state battery technology, with significant advancements expected by 2027 [8][43] Summary by Sections Photovoltaic - March production of photovoltaic modules has increased, driven by a rush in installations due to policy changes, indicating a "small spring" for the sector [3][11] - The overall price levels in the photovoltaic supply chain are expected to stabilize and potentially rebound in Q4 2024, with a focus on companies that can withstand market cycles [14][21] Wind Power - Domestic wind power installations reached 79 GW in 2024, a 5% increase year-on-year, with significant monthly additions in December [4][25] - The market is encouraged by the commencement of offshore wind projects, with a focus on tower and foundation segments [4][26] Energy Storage - The energy storage market is expected to benefit from rising electricity prices in South Africa and strong demand in Australia, leading to potential valuation recovery [8][32] - The introduction of independent energy storage systems in the Guizhou market marks a significant development in the sector [32][33] Hydrogen Energy - The national hydrogen technology company is set to launch an IPO, which is expected to enhance interest and investment in the hydrogen sector [8][38] - Subsidies for hydrogen production in Cangzhou are aimed at promoting the hydrogen industry [40] Electric Grid Equipment - The initiation of four ultra-high voltage projects is expected to drive over 800 billion yuan in investments in the electric grid sector this year [8][41] - Companies involved in traditional grid equipment are recommended for investment due to their stable growth potential [42] Electric Vehicles - The solid-state battery technology is anticipated to revolutionize the electric vehicle market, with significant developments expected by 2027 [8][43] - Major automotive companies are collaborating to enhance battery performance and reduce costs [43][46] Humanoid Robots - The humanoid robotics sector is seeing advancements with companies like Figure AI demonstrating new capabilities, indicating a growing market for automation in logistics [8][48]

Investment Rating - The report gives a "Buy" investment rating for the company [2][11]. Core Viewpoints - The company focuses on innovative pharmaceutical products, with a multi-field layout in the biopharmaceutical industry, aiming to become a leading innovative enterprise [5][17]. - The core products include recombinant human interferon α2b "Andafeng," recombinant human growth hormone "Ansume," and trastuzumab "Ansaiting," among others [5][17]. - The company achieved a revenue of 2.866 billion yuan in 2023, a year-on-year increase of 22.94%, and a net profit of 847 million yuan, up 20.47% year-on-year [6][25]. - The company is expected to see revenue of 2.677 billion yuan in 2024, a decrease of 6.6% year-on-year, but a recovery in subsequent years is anticipated [11][13]. Summary by Sections Company Overview - Established in 1993, the company specializes in the research, production, and sales of biopharmaceuticals, focusing on gene-engineered drugs and diagnostic reagents [17][18]. - The company has been recognized as a national innovative enterprise and has established several technology platforms [17][18]. Financial Performance - The company’s revenue has grown from 636 million yuan in 2015 to 2.866 billion yuan in 2023, with a compound annual growth rate of 20.7% [25]. - In the first three quarters of 2024, the company reported a revenue of 1.921 billion yuan, a decrease of 4.95% year-on-year [6][25]. Product Segmentation - The biopharmaceutical segment is the core business, contributing significantly to overall revenue, with a revenue of 2.1 billion yuan in 2023, accounting for 73.27% of total revenue [28][36]. - The company’s growth hormone product line is expected to see significant market potential, with the domestic growth hormone market projected to grow substantially [39][40]. Market Position - The company holds a leading market share in recombinant human growth hormone, with a 16.9% market share in the domestic market as of 2023 [42]. - The competitive landscape is intensifying, with several players vying for market share in the growth hormone sector [42].

[Table_IndNameRptType] 全球科技 行业周报 [Table_IndRank] 行业评级：增持 报告日期： 2025-03-02 行业指数与沪深 300 走势比较 分析师：金荣 执业证书号：S0010521080002 邮箱：jinrong@hazq.com 分析师：来祚豪 执业证书号：S0010524100001 邮箱：laizh@hazq.com 分析师：刘京松 执业证书号：S0010524090001 邮 箱：liujs@hazq.com 相关报告 ·行业点评：业绩韧性持续验证，关注 估值修复机会 2024-10-03 ·公司深度：联想集团：PC 市场回 暖，AI 服务器有望带动增量 2024-10-1 ·公司深度：谷歌(GOOGL.O)：AI 筑牢 搜索壁垒，云业务打造第二增长曲线 2 024-09-30 ·公司深度：特斯拉(TSLA.O)：短期看 新车型销量及 FSD，中期看能源，长期 看 Optimus2024-09-27 ·公司深度：新大陆：第三方支付盈利 改善，海外战略持续推进 2024-09-27 OpenAI GPT-4.5 上线，AI 利好智驾场景 主要观点： [⚫Ta ...

电子 行业周报 电子行业周报:模拟芯片底部复苏,国补促进消费电子市场 行业评级:增持 报告日期:2025-03-02 行业指数与沪深 300 走势比较 200/ 700/ 10% 电子(申万) 分析师:陈耀波 执业证书号: S0010523060001 郎箱: chenyaobo@hazq.com 分析师:李美贤 执业证书号：S0010524020002 邮箱: limeixian@hazq.com 分析师:刘志来 执业证书号：S0010523120005 邮箱：liuzhilai@hazq.com 分析师:李元晨 执业证书号: S0010524070001 邮箱：liyc@hazq.com 主要观点: ● 本周行情回顾 从指数表现来看,本周(2025-02-24 至 2025-02-28),上证指数周涨 跌幅-1.72%,深圳成指涨跌幅为-3.46%,创业板指数涨跌跌幅-4.87%, 科创 50 涨跌幅为-1.46%,申万电子指数涨跌幅-4.87%。板块行业指 数来看，表现最好的是半导体材料指数,涨幅为+0.42%,印制电路板 表现较弱,跌幅为 11.60%;板块概念指数来看,表现最好的是存储器 指数,涨幅 ...

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The USDA's February report indicates a decrease in global corn and soybean production, while wheat production is expected to rise [1][4] - The global corn supply-demand gap is widening, leading to a decrease in the corn stock-to-use ratio, which is favorable for international corn prices [4][10] - Domestic corn market activity is recovering post-Spring Festival, with strong demand from feed and processing sectors [4][22] Summary by Sections Corn - For the 2024/25 season, global corn production is forecasted at 1.212 billion tons, a decrease of 17.6 million tons from the previous year, primarily due to drought conditions in South America [10][11] - Global corn consumption is projected to increase to 1.238 billion tons, with ending stocks expected to drop to 290 million tons, marking the lowest stock-to-use ratio since the 2016/17 season at 20.3% [10][18] - China's corn production is estimated at 295 million tons, with imports expected to decrease to 10 million tons, reflecting a tightening domestic supply [18][20] Wheat - The USDA forecasts global wheat production for 2024/25 at 794 million tons, an increase of 2.58 million tons from the previous year, driven by higher yields in Kazakhstan and Argentina [29][30] - Global wheat consumption is expected to rise to 804 million tons, with ending stocks projected to fall to 258 million tons, resulting in a stock-to-use ratio of 25.4%, the lowest since the 2015/16 season [29][31] - China's wheat imports are expected to decline to 8 million tons, the lowest level in five years [30] Soybeans - Global soybean production for 2024/25 is projected at 421 million tons, a decrease of 3.5 million tons from the previous year, largely due to adverse weather in South America [6][29] - Global soybean consumption is expected to increase to 406 million tons, with ending stocks projected at 124 million tons, leading to a stock-to-use ratio of 21.1%, the highest since the 2019/20 season [6][29]